Share

December 2020; 10 (6) ResearchOpen Access

Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practice

Carrie M. Hersh, Haleigh Harris, Devon Conway, Le H. Hua
First published February 12, 2020, DOI: https://doi.org/10.1212/CPJ.0000000000000809
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
632

Share

Article Information

vol. 10 no. 6 e53-e65
DOI: 
https://doi.org/10.1212/CPJ.0000000000000809
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received September 23, 2019
  • Accepted December 9, 2019
  • First Published February 12, 2020.

Article Versions

Copyright & Usage: 
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Carrie M. Hersh, DO,
    2. Haleigh Harris, BA,
    3. Devon Conway, MD and
    4. Le H. Hua, MD
  1. Carrie M. Hersh, DO,
    2. Scientific Advisory Boards:

    1. (1) Commercial, Biogen Idec, US Medical MS Franchise Advisory Board (2) Commercial, TEVA, MS Next Generation Advisory Board (3) Commercial, Genentech, US Medical MS Franchise Advisory Board (4) Commercial, Novartis, Siponimod Advisory Board (5) Commercial, EMD Serono, Curious About MS Advisory Board

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Commercial, Genzyme, speaker/consulting honoraria (2) Commercial, Novartis, speaker/consulting honoraria (3) Commercial, Biogen, speaker/consulting honoraria (4) Commercial, Genentech, speaker/consulting honoraria (5) Commercial, EMD Serono, speaker/consulting honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Commercial, Genzyme, speaker/consulting honoraria (2) Commercial, Novartis, speaker/consulting honoraria (3) Commercial, Biogen, speaker/consulting honoraria (4) Commercial, Genentech, speaker/consulting honoraria (5) Commercial, EMD Serono, speaker/consulting honoraria

    Speakers' Bureaus:

    1. (1) Commercial, Genzyme, speakers' bureau (2) Commercial, Novartis, speakers' bureau (3) Commercial, Biogen, speakers' bureau

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Commercial, Biogen (2) Commercial, Genentech (3) Commercial, PCORI

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Haleigh Harris, BA,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Devon Conway, MD and
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I have served as a consultant for Novartis Pharmaceuticals and Tanabe Laboratories.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis Pharmaceuticals

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) National Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Le H. Hua, MD
    5. Scientific Advisory Boards:

    1. (1) Biogen (2) EMD Serono (3) Novartis

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Biogen, speaker honoraria, funding for travel (2) EMD Serono, speaker honoraria, funding for travel (3) Novartis, speaker honoraria, funding for travel (4) Genzyme, speaker honoraria, funding for travel

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Novartis (2) EMD Serono (3) Biogen (4) Genzyme (5) Genentech (6) Celgene (7) TG Therapeutics

    Speakers' Bureaus:

    1. (1) Genzyme (2) Biogen (3) Novartis (4) EMD Serono

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Eric and Sheila Samson Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Lou Ruvo Center for Brain Health (CMH, HH, LHH), Cleveland Clinic, Las Vegas, NV; and Mellen Center for Multiple Sclerosis Treatment and Research (DC), Cleveland Clinic, Cleveland, OH.
  1. Correspondence
    Carrie M. Hersh hershc{at}ccf.org
View Full Text

Article usage

Article usage: February 2020 to December 2020

AbstractFullPdfSource
Feb 20205000134Highwire
Mar 20203070107Highwire
Apr 2020103036Highwire
May 202078043Highwire
Jun 2020162034Highwire
Jul 202091027Highwire
Aug 2020124043Highwire
Sep 202070030Highwire
Oct 2020136019Highwire
Nov 202055021Highwire
Dec 2020191514138Highwire

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.cp.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on The Nerve!

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate The Nerve! Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me